Citation

Muzik M, Marcus SM, Flynn H, Rosenblum KL. Asia Pac. Psychiatry 2010; 2(1): 7-18.

Copyright

(Copyright © 2010, John Wiley and Sons)

DOI

10.1111/j.1758-5872.2010.00051.x

PMID

unavailable

Abstract

Depression during pregnancy is common (∼15%). Routine prenatal depression screening coupled with the use of physician collaborators to assist in connecting women with care is critical to facilitate treatment engagement with appropriate providers. Providers should be aware of risk factors for depression - including a previous history of depression, life events, and interpersonal conflict - and should appropriately screen for such conditions. Depression during pregnancy has been associated with poor pregnancy outcomes including preeclampsia, insufficientweight gain, decreased compliance with prenatal care, and premature labor. Current research has questioned the overall benefit of treating depression during pregnancy with antidepressants when compared to the risk of untreated depression for mother and child. Published guidelines favor psychotherapy above medication as the first line treatment for prenatal depression. Poor neonatal adaptation or withdrawal symptoms in the neonate may occur with fetal exposure in late pregnancy, but the symptoms are mild to moderate and transient. The majority of mothers who decide to stop taking their antidepressants during pregnancy suffer relapsing symptoms. If depression continues postpartum, there is an increased risk of poor mother-infant attachment, delayed cognitive and linguistic skills in the infant, impaired emotional development, and behavioral problems in later life. Bipolar depression, anxiety and substance use disorders, and/or presence of severe psychosocial stress can lead to treatment-resistance. Modified and more complex treatment algorithms are then warranted. Psychiatric medications, interpersonal or cognitive-behavioral therapy, and adjunctive parent-infant/family treatment, as well as social work support, are modalities often required to comprehensively address all issues surrounding the illness. © 2010 Blackwell Publishing Asia Pty Ltd.

Language: en

Keywords

Detection; human; Depression; suicide; sexual abuse; Comorbidity; Pregnancy; alcoholism; Treatment; bipolar disorder; depression; prevalence; screening; social support; infanticide; docosahexaenoic acid; bipolar depression; comorbidity; posttraumatic stress disorder; Edinburgh Postnatal Depression Scale; review; substance abuse; anticonvulsive agent; antidepressant agent; antihypertensive agent; neuroleptic agent; disease predisposition; amfebutamone; cognitive defect; fluoxetine; mirtazapine; nefazodone; paroxetine; serotonin uptake inhibitor; tricyclic antidepressant agent; venlafaxine; priority journal; behavior therapy; cognitive therapy; anxiety disorder; urine retention; lithium carbonate; practice guideline; electroconvulsive therapy; steroid; congenital heart disease; prenatal care; mental stress; cigarette smoking; benzodiazepine derivative; seizure; trazodone; carbamazepine; puerperal depression; weight gain; irritability; mother child relation; unindexed drug; valproic acid; respiratory tract disease; lamotrigine; side effect; atypical antipsychotic agent; duloxetine; withdrawal syndrome; phototherapy; growth retardation; craniofacial malformation; obsessive compulsive disorder; Beck Depression Inventory; folic acid; blood clotting disorder; nervousness; teratogenicity; intestine obstruction; monotherapy; diagnostic and statistical manual of mental disorders; congenital malformation; immunosuppressive agent; mood stabilizer; muscle hypotonia; Center for Epidemiological Studies Depression Scale; preeclampsia; spontaneous abortion; pregnancy outcome; premature labor; bronchodilating agent; anencephalus; icosapentaenoic acid; prenatal exposure; language ability; decongestive agent; pregnancy disorder; neural tube defect; serotonin noradrenalin reuptake inhibitor; craniofacial synostosis; omphalocele; microcephaly; spina bifida